Trial Profile
A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis with Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately from a Japanese Encephalitis Vaccine
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Rabies vaccine (Primary)
- Indications Rabies
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms RABIES-018 BST:017 (V49_23E1)
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK; Novartis Vaccines
- 10 Apr 2023 This trial has been completed in Austria (End Date: 15 Mar 2023), according to European Clinical Trials Database record.
- 03 Jan 2022 Planned End Date changed from 5 Dec 2022 to 18 Nov 2022.
- 03 Jan 2022 Planned primary completion date changed from 5 Dec 2022 to 18 Nov 2022.